Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib and Letrozole in Locally Advanced Breast Cancer
NCT05163106Phase 2Completed
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in breast cancer. Primary endpoint: Change in levels of direct and indirect immunologic biomarkers at Day 180. Started Dec 2022; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05163106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163106.